Clinical Trial News and Research

RSS

CardioNova initiates Phase 1b clinical trial with AtheroNova's AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001.

30 Jul 2014

Researchers establish new strategy to help surgeons see entire tumor in patient

The best way to cure most cases of cancer is to surgically remove the tumor. The Achilles heel of this approach, however, is that the surgeon may fail to extract the entire tumor, leading to a local recurrence.

30 Jul 2014

Diet rich in soy may help feminine hearts, but timing matters

A diet rich in soy may help feminine hearts, but timing matters, finds a new study published online today in Menopause, the journal of The North American Menopause Society.

30 Jul 2014

EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the initiation of an international Phase II study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1).

29 Jul 2014

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use.

29 Jul 2014

University of Bradford researchers devise simple blood test to diagnose cancer

Researchers from the University of Bradford, UK, have devised a simple blood test that can be used to diagnose whether people have cancer or not.

29 Jul 2014

Cardioxyl reports positive results from CXL-1427 Phase I trial for treatment of ADHF

Cardioxyl Pharmaceuticals, Inc. announced today the positive results of a clinical trial demonstrating that CXL-1427, a novel potential treatment for acute decompensated heart failure (ADHF), was well tolerated in healthy volunteers.

28 Jul 2014

Adopting a comprehensive and integrative healing strategy for cancer

The cancer drugs, radiation therapy and cancer surgery available today help millions of people survive their cancer.

27 Jul 2014

XPro1595 drug can protect vulnerable neurons, reduce motor deficits in Parkinson's model

An experimental anti-inflammatory drug can protect vulnerable neurons and reduce motor deficits in a rat model of Parkinson's disease, researchers at Emory University School of Medicine have shown.

26 Jul 2014

Researchers demonstrate novel approach in cervical cancer prevention

A study published online in the International Journal of Cancer earlier this month describes a novel approach to preventing cervical cancer based on findings showing successful reduction in the risk of cervical cancer after removal of a discrete population of cells in the cervix.

26 Jul 2014

FDA issues Complete Response Letter for AcelRx's Zalviso NDA

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's new drug application (NDA) for Zalviso (sufentanil sublingual tablet system).

26 Jul 2014

Galmed reports net loss of $3.9 million for six months ended June 30, 2014

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced financial results for the period ended June 30, 2014.

25 Jul 2014

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Today Biogen Idec announced that the European Commission (EC) has granted marketing authorization for PLEGRIDY (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).

25 Jul 2014

New treatment fights respiratory syncytial virus in children

Researchers at Le Bonheur Children's Hospital and the University of Tennessee Health Science Center announced results of a clinical trial of a new drug shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV).

25 Jul 2014

Paracetamol fails to beat placebo at relieving back pain

Paracetamol is no more effective than placebo at relieving acute lower back pain, according to new clinical trial results.

24 Jul 2014

Deleting enzyme favorably impacts behaviors associated with autistic behaviors

Fragile X syndrome (FXS) is a genetic disorder that causes obsessive-compulsive and repetitive behaviors, and other behaviors on the autistic spectrum, as well as cognitive deficits. It is the most common inherited cause of mental impairment and the most common cause of autism.

24 Jul 2014

TransCelerate selects Cognizant to develop first-of-its-kind, subscription-based platform

Cognizant today announced that it has been selected by TransCelerate BioPharma Inc., a non-profit organization with membership representation from 19 major pharmaceutical companies, to develop a first-of-its-kind, subscription-based platform that will transform the way clinical sites collaborate with pharmaceutical companies on clinical trials.

24 Jul 2014

Cypher Genomics, Illumina partner to facilitate development of genomic-based biomarkers

Cypher Genomics, Inc., the genome informatics company, announced today a co-promotion agreement with Illumina to facilitate the development of genomic-based biomarkers from whole genome sequence data for precision medicine and clinical trials.

From Illumina, Inc. 24 Jul 2014

FDA approves Targiniq ER to treat severe pain

Today, the U.S. Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), an extended-release/long-acting (ER/LA) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

24 Jul 2014

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers.

24 Jul 2014

Clinical Trial News and Research

CardioNova initiates Phase 1b clinical trial with AtheroNova's AHRO-001

Researchers establish new strategy to help surgeons see entire tumor in patient

Diet rich in soy may help feminine hearts, but timing matters

EMD Serono begins MSB0010718C Phase II study in mMCC patients

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

University of Bradford researchers devise simple blood test to diagnose cancer

Cardioxyl reports positive results from CXL-1427 Phase I trial for treatment of ADHF

Adopting a comprehensive and integrative healing strategy for cancer

XPro1595 drug can protect vulnerable neurons, reduce motor deficits in Parkinson's model

Researchers demonstrate novel approach in cervical cancer prevention

FDA issues Complete Response Letter for AcelRx's Zalviso NDA

Galmed reports net loss of $3.9 million for six months ended June 30, 2014

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

New treatment fights respiratory syncytial virus in children

Paracetamol fails to beat placebo at relieving back pain

Deleting enzyme favorably impacts behaviors associated with autistic behaviors

TransCelerate selects Cognizant to develop first-of-its-kind, subscription-based platform

Cypher Genomics, Illumina partner to facilitate development of genomic-based biomarkers

FDA approves Targiniq ER to treat severe pain

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer